Preclinical and phase I studies of an antisense oligonucleotide drug targeting IGF-1R against liver cancer - Supplementary material
收藏数据链接：
官方服务：
资源简介：
Supplementary Table I Target lesion characteristic in each groupSupplementary Table II Summary of adverse events in each group
提供机构：
Taylor & Francis创建时间：
2024-04-04
